Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5395589 | 0.89 | GPR119 (0.42) | GPR119ALDH1A1MAPTMMP13RAB9A | |
| SCHEMBL13923464 | 0.88 | MAPT (0.52) | GPR119ALDH1A1MAPTNR1H2NR1H3 | |
| SCHEMBL5394205 | 0.85 | GPR119 (0.52) | GPR119ALDH1A1MAPTNR1H2NR1H3 | |
| SCHEMBL3921237 | 0.82 | GPR119 (0.53) | GPR119MAPTRORC | |
| SCHEMBL13940334 | 0.81 | GPR119 (0.50) | GPR119ALDH1A1MAPTSMN1; SMN2NR1H2 | |
| SCHEMBL21800250 | 0.80 | ADAMTS5 (0.38) | GPR119ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL5395741 | 0.78 | HDAC6 (0.44) | GPR119ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL5398512 | 0.78 | SMN1; SMN2 (0.46) | GPR119ALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL5408519 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5390992 | 0.77 | MAPT (0.44) | GPR119ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214680-B2 | 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | SLC6A4, TPH1, HTR1D | GPR119 563/4885ALDH1A1 1543/4885KDM4E 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.